Avtor/Urednik		Kranjc Brezar, Simona; Prevc, Ajda; Nikšić Žakelj, Martina; Brožič, Andreja; Čemažar, Maja; Strojan, Primož; Serša, Gregor
Naslov		Synergistic effect of cisplatin chemotherapy combined with fractionated radiotherapy regimen in HPV-positive and HPVnegative experimental pharyngeal squamous cell carcinoma
Tip		članek
Vol. in št.		, št. Vol. 10
Leto izdaje		2020
Obseg		str. [1-9]
ISSN		2045-2322 - Scientific reports
Jezik		eng
Abstrakt		in a favorable prognosis for HPV-positive patients treated with radiation alone or with concurrent platinum-based chemotherapy. The degree of radiosensitivity in fractionated regimens has not yet been fully explored; therefore, in this study, the radiosensitivity of HPV-negative tumors (FaDu) was compared to that of HPV-positive tumors (2A3) subjected to concurrent cisplatin chemotherapy and fractionated versus isoeffective single-dose tumor irradiation in immunodeficient mice. HPV-positive tumors were approximately 5 times more radiosensitive than HPV-negative tumors, irrespective of the irradiation regimen. In both tumor models, concurrent cisplatin chemotherapy and the fractionated regimen induced significant tumor radiosensitization, with a 3- to 4-fold increase in the tumor growth delay compared to that of single-dose irradiation. Furthermore, the degree of radiosensitization induced by cisplatin chemotherapy concurrent with the fractionated irradiation regimen was much higher in HPV-positive tumors, where a synergistic antitumor effect was observed. Specifically, after combined therapy, a 26% higher survival rate was observed in mice with HPV-positive tumors than in mice with HPV-negative tumors. These data suggest that HPV-positive tumors are more radiosensitive to fractionated regimen than to single-dose irradiation with concurrent cisplatin chemotherapy acting synergistically to irradiation.
Proste vsebinske oznake		cisplatin kemoterapija ploščatocelični rak rak glave in vratu eksperimentalna onkologija cisplatin chemotherapy squamous cell carcinoma oropharyngeal cancer experimental oncology